Chongqing Taiji Industry (SHA:600129) received a drug registration certificate from China's National Medical Products Administration for its butorphanol tartrate injection, according to a Tuesday filing with the Shanghai bourse.
The drug is indicated for cancer and postoperative pain, the company said in its filing.
Total sales of the drug reached 1.63 billion yuan in 2025, according to market data cited in the filing.